Nuance Pharma (Shanghai) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-08-12
- Employees
- 11
- Market Cap
- -
- Website
- https://www.nuancepharma.com
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 28
- Registration Number
- NCT05758428
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 3
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 488
- Registration Number
- NCT05743075
- Locations
- 🇨🇳
1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Pharmacokinetic Study of Intravenous NTM-001 in Healthy Chinese Subjects
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT05382546
- Locations
- 🇨🇳
HUK Phase 1 clinical trials center, Hong Kong, Hong Kong, China
Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT04158102
- Locations
- 🇨🇳
HUK Phase 1 clinical trials center, Hong Kong, Hongkong, China
© Copyright 2025. All Rights Reserved by MedPath